Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Currus Biologics, an Australia-based cancer immunotherapy developer spun out of Peter MacCallum Cancer Centre, has secured A$10m ($7.7m) in a funding round led by the Brandon Capital Partners-managed Medical Research Commercialisation Fund, with participation from multi-university venture fund Uniseed, according to the Australian Financial Review. Currus is the oncology research centre’s first investor-led spinout. It will use the money to advance its research aimed at solid tumours, including breast and pancreatic cancers, towards a product suitable for human clinical trials.
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
